Iovance Biotherapeutics reported record financial results for the second quarter 2026, characterized by the accelerating commercial adoption of Amtagvi. The company achieved a significant expansion in its authorized treatment center network and improved its gross margin to 56% through manufacturing efficiencies.
Key Highlights
- Total product revenue reached $99.3 million, representing 66% year-over-year growth and a 39% sequential increase from the first quarter.
- U.S. Amtagvi revenue totaled approximately $91 million, fueled by a network that has grown to 95 authorized treatment centers across the U.S., Canada, and Australia.
- Operating expenses showed signs of stabilization as research and development costs decreased 6% sequentially to $58.9 million due to improved operational scale.